Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
关于子公司获得化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 93% confidence The document is a stock exchange announcement by a listed company informing investors that its subsidiary received a regulatory approval notice for a chemical API from the National Medical Products Administration. It does not contain financial statements, management discussion, or proxy materials, nor is it an earnings release or board change. It is a general compliance/regulatory announcement about an operational development. Therefore it falls under the fallback category Regulatory Filings (RNS).
2026-06-01 Chinese
关于继续公开挂牌转让全资子公司股权的进展公告
Regulatory Filings Classification · 72% confidence The document is a short regulatory announcement (“进展公告”) reporting the progress of a planned public listing-based transfer of its wholly owned subsidiary’s equity. It does not contain financial statements, management discussion, or detailed deal documentation; it simply updates investors on the transaction’s status. It therefore is not itself an M&A transaction filing (e.g., merger/tender offer) nor a financing report. Under the classification scheme, it falls into the catch-all “Regulatory Filings” category (RNS).
2026-05-22 Chinese
关于子公司获得注射用磷酸特地唑胺药品注册证书的公告
Regulatory Filings Classification · 82% confidence The document is a corporate announcement that the company’s subsidiary has obtained a drug registration certificate from the National Medical Products Administration. There is no financial data, management change, share issuance, or meeting materials. It is a general regulatory announcement of compliance/approval information and thus falls under the generic “Regulatory Filings” category (RNS).
2026-05-21 Chinese
关于公司独立董事辞职的公告
Board/Management Information Classification · 85% confidence The document is an official announcement by the company board regarding the resignation of an independent director and related changes in board composition. This directly matches the definition of a Board/Management Information filing.
2026-05-15 Chinese
关于继续公开挂牌转让全资子公司股权的进展公告
Capital/Financing Update Classification · 75% confidence The document is an official corporate announcement by *ST赛隆 regarding the progress (“进展公告”) of continuing to publicly list and transfer 100% equity of its wholly‐owned subsidiary. It describes details of the open bidding process, timelines, and next steps. It is not a financial report (10‐K, IR), not an AGM or vote result, nor a management change. It is neither a dividend notice nor a share repurchase. Rather, it relates to a capital structure transaction—specifically an asset disposal via public listing of subsidiary shares. This falls under “Capital/Financing Update (CAP)” as it updates on a significant capital structure change.
2026-05-14 Chinese
关于收到终止上市事先告知书的公告
Delisting Announcement Classification · 100% confidence The document is an official announcement from a company regarding receipt of a notice about the termination of its stock listing by the Shenzhen Stock Exchange. It references regulatory rules and procedures for delisting, including rights to hearings and appeals. The document does not contain financial statements or detailed financial data but is a formal notice about the delisting process. The document length is short (972 characters), and it serves as an official delisting announcement rather than a financial report or audit. Therefore, it fits the category of a Delisting Announcement (DLST).
2026-05-07 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.